The Cystic Fibrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cystic Fibrosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued products.
GlobalData tracks 128 drugs in development for Cystic Fibrosis by 101 companies/universities/institutes. The top development phase for Cystic Fibrosis is preclinical with 54 drugs in that stage. The Cystic Fibrosis pipeline has 116 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Cystic Fibrosis pipeline products market are: Sionna Therapeutics, Vertex Pharmaceuticals and Eloxx Pharmaceuticals.
The key targets in the Cystic Fibrosis pipeline products market include Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6), 30S Ribosomal Subunit (30S RNA), and Anoctamin 1 (Discovered On Gastrointestinal Stromal Tumors Protein 1 or Oral Cancer Overexpressed Protein 2 or Transmembrane Protein 16A or Tumor Amplified And Overexpressed Sequence 2 or TMEM16A or ANO1).
The key mechanisms of action in the Cystic Fibrosis pipeline product include Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6) Activator with 44 drugs in Pre-Registration. The Cystic Fibrosis pipeline products include 11 routes of administration with the top ROA being Inhalational and 15 key molecule types in the Cystic Fibrosis pipeline products market including Small Molecule, and Gene Therapy.
Cystic Fibrosis overview
Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose, and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning medications, bronchodilators, and oral pancreatic enzymes.
For a complete picture of Cystic Fibrosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
